Browsing by Author "Laker, Eva Agnes Odongpiny"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item An Observational Study in an Urban Ugandan Clinic comparing Virological Outcomes of Patients Switched from first-line Antiretroviral Regimens to Second-line Regimens containing Ritonavir-boosted Atazanavir or Ritonavir-boosted Lopinavir(BMC Infectious Diseases, 2019) Laker, Eva Agnes Odongpiny; Nabaggala, Maria Sarah; Kaimal, Arvind; Nalwanga, Damalie; Abdu Musubire, Abdu Musubire; Kiragga, Agnes; Lamorde, Mohammed; Parkes- Ratanshi, RosalindThe World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients during the roll out of routine viral load monitoring, who had switched to boosted second- line regimens of either atazanavir or lopinavir.Item The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir‑Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women(Drug Safety, 2020) Laker, Eva Agnes Odongpiny; Arinaitwe, Arnold; Owarwo, Noela; Onzia, Annet; Nasasira, Benson; Wailagala, Abdullah; Kalule, Ivan; Anguzu, Godwin; Kiragga, Agnes; Lwanga, Isaac; Castelnuovo, Barbara; Musomba, Rachel; Lamorde, MohammedIn May 2018, the World Health Organization and other regulatory authorities released a safety alert for dolutegravir related to a risk of neural tube defects among women exposed to dolutegravir at the time of conception. Models of how drug safety information can be shared effectively in the shortest time are necessary to prevent interruptions of public health programs. We sought to describe an implementation process to inform and support women already on dolutegravir-based regimens at the time of conception to make informed choices following the safety alert of a potential teratogenicity risk. We describe the choices made by women, as well as determine the factors associated with women’s choices to switch off dolutegravir.